Dr. Dennis Brown
Chairman of the Board
Dr. Brown is a founder and Chief Scientific Officer and Director of Del Mar Pharmaceuticals. He has over thirty years of drug discovery and development experience and has served as Chairman of Mountain View Pharmaceuticals’ Board of Directors. He founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals (ASX: CXS/NASDAQ: CXSP), of which he served as President and a Director until 2009. ChemGenex was then acquired by US biopharmaceutical company Cephalon, which itself was then acquired by Teva Pharmaceutical Industries in 2011 for $6.8 billion.
Dr. Brown was co-founder of Matrix Pharmaceutical, Inc., where he served as Vice President of Scientific Affairs and later Vice President of Discovery Research. He has served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in Radiation and Cancer Biology (1979), all from New York University. Dr. Brown is also an inventor with 34 US patents and patent applications.
Chief Executive Officer, Chief Financial Officer and Director
A Canadian businessman and a founding member of Cell Source. Since Cell Source Israel's inception, Mr. Shimrat served as a Director, Chief Financial Officer and, in October 2013, he was appointed Chief Executive Officer. Previously, Mr. Shimrat served as an Executive Vice President and Division Head at First International Bank of Israel (FIBI), where he founded and led the strategic planning function, including planning, strategy, strategic marketing & branding and project management oversight functions. He led a successful rebranding and repositioning of the bank and during his tenure the bank's ROE was doubled.
Previously, Mr. Shimrat worked as an international management consultant, chiefly at McKinsey & Co., and he led successful major profit improvement programs for top tier financial institutions including Barclays in England and the Commonwealth Bank of Australia. He began his management consulting career at Bain & Company, where he participated in the development of a new global retail strategy for Citibank. He holds an MBA with Distinction from the Ivey Business School of the University of Western Ontario in Canada.
An Israeli entrepreneur and co-founder of Cell Source, he was previously been involved in the development of two successful cell therapy technology firms. He was a founding member of the cell stem therapy company Brainstorm (NASDAQ:BCLI) a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD). He served as COO in 2004 and CEO from 2005 to 2007.
Mr. Drucker was also among the founders of Pluristem (NASDAQ:PSTI) a clinical-stage biotechnology company using human placental cells and a proprietary, platform to develop cell therapies for a broad spectrum of diseases, including peripheral artery disease and muscle injury, where he served as Director in 2004 and 2005. Previously VP Business Development at a renewable energy technology firm, he has served as an executive in the diamond industry and a successful marketing strategy and corporate finance consultant.
A Director of Cell Source Israel since November, 2011 and of our Board of Directors since June 30, 2014, and is a Canadian businessman who has owned and managed various Canadian enterprises since 1968. In the mid 1970's David was one of the founders of TNT Appliances, a coin laundry and appliance sales and service company, primarily serving the Canadian burgeoning multi-family apartment industry. The company grew to be the second largest coin laundry in Canada and was sold in and about 2002. While owning and managing TNT, David was also involved in many real estate acquisitions both through TNT and the Zolty family real estate portfolio. David has received an honors BA and has done his post graduate work at the University of Toronto. He is also involved in a number of local charities and is a long standing board member of Camp Agudah Toronto, a children's summer camp which have facilities at Port Carling, Ontario.
Has been a Director of Cell Source Israel since November, 2011 and of our Board of Directors since June 30, 2014, and is a Canadian business executive with over 25 years' experience in real estate and commerce. Since 1985, he has served as Owner and CEO of Saucham Holdings Ltd., a private real estate holding and development company active throughout Canada. He is, and has been for more than five years, a managing partner and Director of The Zolty Group, a private company specializing in the development and ownership of high rise multi-unit residential buildings in Canada and the United States. He continues to act as Director of numerous private business related enterprises in the high tech, medical, and laser technology fields, and is a Director of an array of non-profit educational and vocational institutions.